505(b)(2)-Like Pathway For Biologics May Gain Renewed Interest With Senate User Fee Bill Pending

 
• By Derrick Gingery
  
New pathway
Could the FDA user fee bill include a new pathway for so-called biobetters? • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics